We conducted a phase I trial to determine the maximum tolerated dose (MTD) of clofarabine with high-dose busulfan followed by allogeneic stem cell transplantation (SCT) in patients with high-risk and refractory acute leukemia. Patients received intravenous busulfan 0.8 mg/kg every 6 h on days À6 to À3 and clofarabine 30-60 mg/m 2 per day on days À6 to À2. Graft-versus-host disease prophylaxis included sirolimus plus tacrolimus (days À2 to þ 180). A total of 15 patients, median age 48 (30-58) years, with acute leukemia that was relapsed and refractory (n ¼ 8), primary refractory (n ¼ 6), or in CR2 (n ¼ 1), were treated at four clofarabine dose levels: 30 (n ¼ 3), 40 (n ¼ 3), 50 (n ¼ 3) and 60 mg/m 2 per day (n ¼ 6) with busulfan. All engrafted, and the MTD was not reached. Grades 3-4 nonhematological toxicities included vomiting (n ¼ 3), mucositis (n ¼ 9), hand-foot syndrome (n ¼ 1), acute renal failure (n ¼ 1) and reversible elevation of aspartate aminotransferase/alanine aminotransferase (n ¼ 10). The 1-year event-free survival was 53% (95% confidence interval: 33-86%), and the 1-year overall survival was 60% (95% confidence interval: 40-91%). Given the good tolerability and promising results, we recommend clofarabine 60 mg/m 2 per day Â 5 days as a phase II dose in combination with busulfan (12.8 mg per kg total dose) for further study as a myeloablative regimen for allogeneic SCT for high-risk acute leukemia.
Introduction
Allogeneic stem cell transplantation (SCT) remains an important curative option for many patients with acute leukemia. 1, 2 Although reduced-intensity regimens appear to be better tolerated and allow older patients the opportunity for transplantation, recent evidence indicates that dose-intensity is important for disease control in spite of a graft-versus-leukemia effect, particularly in patients at high-risk of relapse. 3, 4 The combination of cyclophosphamide with busulfan (BuCy2) is a commonly used regimen for allogeneic HSCT in patients with acute leukemia, 5 although it is associated with significant toxicity. [6] [7] [8] Although cyclophosphamide adds significant immunosuppression, 9 its dose-limiting cardiac toxicity and risks of hemorrhagic cystitis and hepatic sinusoidal obstruction syndrome remain problematic. [6] [7] [8] 10, 11 Recently, the substitution of fludarabine for cyclophosphamide in combination with targeted oral or intravenous busulfan has suggested that disease control equivalent to the BuCy2 regimen can be achieved with reduced toxicity. 12, 13 Although fludarabine has significant immunosuppression to prevent graft rejection, fludarabine has only modest anti-leukemic activity. 14 Clofarabine (2-chloro-2-fluoro-deoxy-9-D-arabinofuranosyladenine) is a second generation purine nucleoside analogue designed to maintain the favorable qualities of fludarabine without dose-limiting neurotoxicity. 15 In particular, single agent clofarabine is active in heavily pre-treated, relapsed and/or refractory patients with acute lymphoblastic leukemia and acute myeloid leukemia, [16] [17] [18] including older patients with high-risk features. 19, 20 In addition, in vitro studies have shown synergistic activity between clofarabine and alkylating agents. 21 We, therefore, hypothesize that the substitution of clofarabine for fludarabine, in combination with high-dose busulfan may be a well-tolerated preparative regimen with improved anti-leukemic activity for patients undergoing allogeneic HSCT. As an initial step, we conducted a phase I clinical trial to determine the maximum tolerated dose (MTD) of clofarabine in combination with high-dose busulfan and allogeneic HSCT in patients with high-risk and refractory acute leukemia (ClinicalTrials.gov Identifier: NCT00477542).
Patients and methods

Patient and donor eligibility
Patients were eligible if they had acute myeloid leukemia or acute lymphoblastic leukemia that was primary refractory, relapsed and refractory (45% bone marrow blasts or extramedullary disease), or who were in second or subsequent complete remission (CR). Patients also had to be 18-60 years old, have a Karnofsky performance status X70%, a left ventricular ejection fraction 445%, DLCO 450%, creatinine clearance 460 ml/min/1.73 m 2 , and serum bilirubin, aspartate aminotransferase and alanine aminotransferase (ALT) levels o2 Â upper limits of normal. Patients were excluded if they had a previous HSCT, central nervous system leukemia, or if they were seropositive for HIV. Donors were eligible if they were related and matched at 5 or 6 of the 6 human leukocyte antigen-matched loci (human leukocyte antigen-A, -B and -DRB1), or unrelated and 10 of 10 antigenmatched (human leukocyte antigen-A, -B, -C, -DRB1 and -DQB1) by high-resolution typing. The study was approved by the Institutional Review Board of Indiana University. All patients and donors gave informed consent. The study was conducted in accordance with the Declaration of Helsinki.
Study design and treatment plan
Busulfan was administered at 0.8 mg/kg (lower of actual or ideal body weight) intravenously over 2 h every 6 h on day À7 to À4 (16 doses), and the dose not adjusted according to pharmacokinetic monitoring. Clofarabine was administered as a daily 1-h intravenous infusion for 5 days on days À6 to À2, with the dose escalated in four successive cohorts: 30, 40, 50 and 60 mg/kg per day. On days À6 to À4, when both drugs were administered on the same day, clofarabine was infused 1-2 h before busulfan. Corticosteroids were not used before clofarabine infusion for prophylaxis of hand-foot syndrome. Bone marrow or PBSC were infused on day 0, and growth factors were not administered. Sirolimus and tacrolimus were administered for graft-versus-host disease (GvHD) prophylaxis, starting day À3 until day þ 100 to maintain a serum level of 5-10 ng/ml for both drugs, followed by tapering through day þ 180. All patients received fluconazole, acyclovir and ciprofloxacin prophylaxis. Preemptive treatment with valganciclovir was instituted if cytomegalovirus activation was detected on plasma monitoring in the first 100 days after transplantation. No specific therapy was used for prevention of sinusoidal obstruction syndrome.
A standard 3 þ 3 trial design was followed. Three patients were enrolled on the first clofarabine dose level. If one of the three patients experienced dose limiting toxicity (DLT; defined below) at a given dose level, three more patients were treated at that dose level. If no DLT was observed in any of the three patients or in one of the six patients, the dose was escalated to the next level. If two or more patients experienced DLT, the MTD was exceeded, and three additional patients were to be treated at the next lower dose. All patients assigned to a dose level were followed until day þ 30 before dose escalation.
Definitions
Adverse events were graded using National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE v3.0). DLT was defined as any grade 3 or 4 non-hematologic toxicity (except alopecia, nausea and vomiting, mucositis, fatigue and correctable biochemical abnormalities, as these are reversible and commonly observed toxicities following myeloablative chemotherapy) that did not resolve to pgrade 2 by day þ 30. The MTD was defined as the dose level at which two out of six patients experienced DLT.
Neutrophil engraftment was defined as recovery of the absolute neutrophil count to 40.5 Â 10 9 /l for 3 consecutive days after treatment-induced nadir. Platelet engraftment was defined as the first day of the platelet count 420 Â 10 9 /l without transfusion for 7 consecutive days. Acute and chronic GvHD were graded according to standard criteria. 22, 23 Chimerism was assessed from whole bone marrow and/or peripheral blood on days þ 30 and þ 100 using analysis of short tandem repeat loci. 24 Response was assessed at day þ 30 and was defined according to recently reported European LeukemiaNet criteria. 25 Relapse was defined by 45% blasts in marrow aspirate or development of extramedullary leukemia in patients with previously documented CR. Event-free survival (EFS) was measured from the date of transplantation to treatment failure, relapse, or death from any cause; otherwise patients were censored on the date of last follow-up. Overall survival (OS) was measured from the date of transplantation until death from any cause, censoring for patients alive on date of last follow-up.
Pharmacologic assays and pharmacokinetic analysis
Plasma clofarabine samples were obtained on day À6 before infusion, at the end of infusion, and at 2, 3, 4, 5, 6 and 24 h after the start of dosing. In addition, samples were also collected immediately before infusion, at the end of infusion and at 6 and 24 h after subsequent doses on days À5 to À2. Clofarabine was extracted from plasma and quantified by high pressure liquid chromatography-tandem mass spectrometry (MS/MS) as previously described. 26 For busulfan, blood was sampled in association with the first and ninth infusion, and in each case collected immediately before infusion, at the end of infusion, and at 135 and 150 min, and at 3, 4, 5 and 6 h after the start of infusion. Busulfan plasma levels were assayed using gas chromatography-mass spectrometry, with a dynamic concentration range of 25-4500 ng/ml and coefficient of variation of o8%.
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Concentration-time data were analyzed by a non-compartmental approach using WinNonlin v4.1 (Pharsight, Mountain View, CA, USA). The area under the plasma concentration curve (AUC) was calculated for busulfan following the first (AUC 1st dose ) and ninth (AUC 9th dose ) doses. The following pharmacokinetic parameters were calculated for clofarabine: maximum plasma concentration (C max ), terminal elimination constant (k el ), terminal half-life (t 1/2 ) and AUC from time zero to the last concentration for each day of infusion, with the average AUC of all doses of clofarabine also calculated (AUC av ). In addition, the area under the plasma concentration curve extrapolated to infinity (AUC 0-N ) was estimated from plasma levels obtained following the first dose (day À6) and the systemic clearance was calculated from the dose and AUC 0-N .
Statistical analysis
The primary objective was to determine the MTD of clofarabine when combined with high-dose busulfan for allogeneic HSCT. Secondary objectives were safety and tolerability, response rate, EFS and OS. Summary statistics were used to describe patient characteristics, times to engraftment, percent donor chimerism and response rates. EFS and OS were estimated using the Kaplan-Meier method. Safety was monitored by an independent Data Safety Monitoring Board according to institutional requirements.
Results
Patient characteristics
A total of 15 patients were enrolled between June 2007 and June 2009. The specific patient characteristics are shown in Table 1 . The median age was 48 (range: 30-58) years. In total, 13 patients had acute myeloid leukemia and two had acute lymphoblastic leukemia. All, but one patient had chemotherapy-refractory disease at the time of transplantation, either primary induction failure (n ¼ 6) or refractory relapse (n ¼ 8).
Patients received a median of 2 (range, 1-3) previous lines of treatment. The median percentage of bone marrow blasts was 12% (3-88%), with 6 patients having X25% blasts. In all, 12 patients also had circulating blasts. One patient received bone marrow from an unrelated donor and 14 received PBSC from related (n ¼ 9) or unrelated (n ¼ 5) donors. The median hematopoietic cell transplantation-specific comorbidity index High-dose clofarabine/busulfan in acute leukemia SS Farag et al.
score was 2 (range: 0-4), with specific comorbidities as shown in Table 1 .
Engraftment
All patients had neutrophil engraftment. The median time to an absolute neutrophil count 40.5 Â 10 9 /l was 16 (range: 12-22) days. The median time to a platelet count 420 Â 10 9 /l was 15 (range: 10-42) days. Only one patient treated at dose level 1 (30 mg/m 2 clofarabine) failed to achieve platelet recovery and remained platelet transfusion-dependent. This patient received a bone marrow graft from an unrelated donor with a CD34 þ cell dose of only 0.7 Â 10 6 /kg. Donor chimerism was almost complete early after transplantation (Table 2) . At day þ 30, the median donor chimerism was 99% (range: 69-100%). The percentage of donor chimerism remained stable or increased in all, but 1 of 12 patients evaluable at day þ 100; median donor chimerism 100% (range: 87-100%). Two patients died of leukemia before day þ 100, and one patient whose disease failed to go into CR following transplantation had a reduction in donor chimerism associated with disease progression (Table 2 ).
Toxicity
The distribution of clinically significant grades 3-4 nonhematological toxicities according to clofarabine dose level are shown in Table 3 . The most frequent grade 3-4 toxicity was asymptomatic and reversible elevation of ALT and aspartate aminotransferase. The median ALT levels from clofarabine administration to day þ 30 are shown in Figure 1a . As shown, the pattern of ALT elevation was very consistent, with ALT level peaking on days À1 or 0, then falling to baseline by day þ 10 in all patients, and therefore did not constitute DLT. There was no significant difference in the peak ALT level between different clofarabine dose levels (Figure 1b) . A similar pattern and degree of elevation of aspartate aminotransferase was also observed (data not shown). In contrast, the bilirubin level and alkaline phosphatase levels remained within normal range or increased to grade 1 in all patients (data not shown).
Other grades 3-4 toxicities were mucositis, diarrhea, and nausea and vomiting, although these did not occur more frequently with clofarabine dose-escalation (Table 1) . One patient treated at the 30 mg/m 2 dose developed sinusoidal obstruction syndrome documented by liver biopsy, although this resolved by day þ 30 and did not meet criteria for DLT. The same patient also developed diffuse alveolar hemorrhage and grade 3 acute renal insufficiency associated with sepsis; both also resolved and did not meet criteria for DLT. One patient at dose level 4 developed thrombotic microangiopathy, which was attributed to sirolimus and tacrolimus and promptly resolved upon discontinuation of these drugs. Another patient, treated at dose level 4, developed acute renal failure on day þ 14 associated with supratherapeutic levels of tacrolimus, although a contribution by clofarabine could not be excluded. As the serum creatinine did not resolved to grade 1 by day þ 30, the event was considered a potential DLT and the 60 mg/m 2 cohort was expanded to six patients; no additional renal toxicity was observed. No further dose-escalation of clofarabine was performed, and a MTD for clofarabine was, therefore, not reached.
Treatment outcome
Of 14 patients transplanted with active chemotherapy-refractory leukemia, 12 achieved a CR (n ¼ 10) or CRi (n ¼ 2) on day þ 30 for an overall response rate of 86%. Two patients with refractory High-dose clofarabine/busulfan in acute leukemia SS Farag et al.
disease, treated at dose levels 2 and 3, respectively, failed to achieve CR or CRi (Table 2) . Two patients died in remission; one treated at dose level 1 died on day þ 104 from gram negative sepsis and multiorgan failure in the context of grade 3 acute GvHD, and another treated at dose level 2 died on day þ 531 of chronic GvHD for a total treatment-related mortality of 13%. Overall, two of 15 patients, both treated at dose level 1, developed acute GvHD; one grade 3 involving skin and gut (see above), and another grade 1 involving skin only. Four of the 13 patients surviving beyond 105 days developed extensive stage chronic GvHD. Of 13 patients in CR or CRi at day þ 30, four relapsed within 6 months of transplantation. After a median follow-up of 593 (range: 406-1140) days for surviving patients, the median EFS and OS are 531 and 609 days, respectively. The 1-year EFS is 53% (95% confidence interval: 33-86%) and the 1-year OS is 60% (95% confidence interval: 40-91%), with seven patients remaining alive and in ongoing CR beyond 406 to 1140 days post-transplant.
Plasma pharmacokinetics studies and clinical correlations
Clofarabine pharmacokinetic parameters are summarized in Table 4 . Although substantial interpatient variability was observed, there was a significant linear relationship between C max (r 2 ¼ 0.43; P ¼ 0.008) and AUC 0-N (r 2 ¼ 0.51; P ¼ 0.003) and clofarabine dose (Figures 2a and b) . No significant differences in other pharmacokinetic parameters were observed between dose groups. Significantly, there was no correlation between C max or AUC av and peak transaminase levels (Figures  2c and d ; data shown only for ALT).
Also, there was no significant difference in the AUC 1st dose and AUC 9th dose of busulfan with clofarabine dose, indicating absence of any significant pharmacokinetic interaction between the two drugs (data not shown).
Discussion
We describe the first study evaluating high-dose clofarabine in combination with busulfan as a myeloablative preparative regimen for allogeneic HSCT, and have shown the feasibility and safety of the combination with clofarabine doses up to 60 mg/m 2 per day for 5 days. Clofarabine is a newer generation purine nucleoside analogue that, like fludarabine, must be converted intracellularly to the 5 0 -triphosphate form by deoxycytidine kinase to be active. 28 Clofarabine triphosphate inhibits DNA synthesis and repair through inhibition of DNA polymerases and ribonucleotide reductase, 29 leading to depletion of intracellular deoxynucleotide triphosphate pools, and inhibition of DNA strands elongation during synthesis. 28, 29 Compared with fludarabine triphosphate, however, the triphosphate of clofarabine is more active in activation of caspase 9, (see ref. 30 ) and unlike triphosphates of other purine analogues, it directly affects the mitochondrial membrane leading to release of pro-apoptotic factors. 31 Consistent with this data, clofarabine has shown greater anti-leukemia activity compared with fludarabine, and therefore, may be a better agent to combine with high-dose busulfan for HSCT. High-dose clofarabine/busulfan in acute leukemia SS Farag et al.
In a phase I trial, the MTD of single agent clofarabine in adults with acute leukemia was defined as 40 mg/m 2 per day when given for 5 days, with hepatotoxicity being dose limiting. 18 In the same trial, however, pharmacologic studies showed there was a significant dose-dependent increase in sustained inhibition of replication of leukemic blasts over 24 h, with only the Table 4 Clofarabine pharmacokinetic parameters
AUC 0-N (h*mg/ml) 6.57 ± highest dose tested, 55 mg/m 2 per day, leading to complete sustainability of inhibition of DNA synthesis until the next dose, 18 providing rationale for dose-escalation. Importantly, we have shown that in combination with high-dose busulfan, clofarabine may be safely escalated to doses up to 60 mg/m 2 per day, which may be expected to provide superior anti-leukemic activity than lower doses. Although asymptomatic elevation of transaminases was also observed in our study, the change followed a predictable time course with complete resolution in all patients by day þ 10. Unlike our study, the previously reported phase I trial in adults with acute leukemia defined the MTD for clofarabine based on grade 3-4 transaminase elevations regardless of reversibility. 18 We contend that if reversibility was considered in the definition of DLT, further dose-escalation of clofarabine may have been feasible. In addition, within the limitations of our sample size, we also did not observe any relationship between clofarabine dose, C max or AUC av and peak transaminase elevation. This is consistent with a similar observation where elevation of transaminases was not related to dose in another phase I trial where doses of clofarabine 30-70 mg/m 2 per day for 5 days were administered in combination with high-dose etoposide and cyclophosphamide. 32 Our data supports further investigation of high-dose clofarabine, as also suggested by others. 33 It should be noted that in our study clofarabine was used in combination with four times per day dosing of busulfan, although recent data suggests that lower doses of clofarabine may be safely administered in combination with more convenient schedule of once daily dosing of busulfan. 34 Other toxicities, including mucositis and diarrhea, are similar to those previously reported for patients receiving either clofarabine or high-dose busulfan. The only potential doselimiting toxicity observed was acute renal failure in one patient who received clofarabine 60 mg/m 2 per day. Although this toxicity developed in the setting of high tacrolimus levels, a possible causal relationship to clofarabine could not be excluded necessitating expanding this dose level to six patients. None of the five additional patients receiving 60 mg/m 2 per day developed acute renal failure. Despite substantial interpatient variability in C max and AUC at any given clofarabine dose, there was no association between plasma pharmacokinetic parameters and toxicity. Although the combination of clofarabine with busulfan appears to be well tolerated, as shown in this trial and by other using lower doses of clofarabine, 34 the combination of clofarabine with cytarabine and anti-thymocyte globulin has recently been reported to be associated with significant morbidity and mortality in a small study. 35 It is likely that the drugs combined with clofarabine, as well as patient selection, significantly affect the tolerability of the regimen.
Notwithstanding the small sample size, clofarabine appeared to provide sufficient immunosuppression for engraftment of both related and unrelated hematopoietic progenitor cells. Myeloid and platelet engraftment kinetics were similar to those reported using the fludarabine/busulfan regimen. 12, 13 In addition, highlevel donor chimerism was achieved in the majority of patients by day þ 30 and was sustained or increased by day þ 100 in the absence of leukemic relapse, indicating that engraftment is possible even at lower clofarabine doses when combined with busulfan. On the other hand, when combined with cytarabine and anti-thymocyte globulin in a reduced intensity regimen, only mixed donor chimerism ranging between 60-75% was achieved in three of four evaluable acute myeloid leukemia and myelodysplasia patients, indicating a lower dose of clofarabine (40 mg/m 2 per day Â 5 days) may not be sufficiently immunosuppressive in such a regimen. 35 Although not the primary endpoint, the clinical outcome of patients treated with high-dose clofarabine and busulfan was quite impressive, given the refractory nature of leukemia in all, but one patient. Durable remissions were observed in 9 patients, with very encouraging 1-year event-free and OSs of 53 and 60%, respectively. This compares very favorably with results of previous studies where the 1-year survival for similar refractory leukemia patients has generally been 25% or less. 36, 37 It should be noted, however, that similar results have been reported in 75 high-risk acute leukemia and myelodysplasia patients using a sequential regimen of chemotherapy (FLAMSA) followed by reduced-intensity conditioning and allogeneic SCT. 38 Although the clofarabine and busulfan regimen may be simpler to administer because of its shorter schedule, the relative efficacy of the two approaches is currently unknown. Nonetheless, our results strongly suggest that high-dose clofarabine and busulfan should be studied further, particularly in patients with refractory or high-risk disease where more conventional preparative regimens are associated with poor outcomes.
We conclude that high-dose clofarabine and busulfan are a novel and well-tolerated preparative regimen for allogeneic HSCT, and may provide better anti-leukemic activity than currently used regimens. Further investigation to better assess the efficacy and safety of this regimen, with a recommended phase II dose of clofarabine of 60 mg/m 2 per day for 5 days together with intravenous busulfan (12.8 mg/kg total dose), is justified.
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